Last updated: February 19, 2026
Aminoglutethimide, a drug historically used to treat Cushing's syndrome and breast cancer, faces a complex landscape of ongoing research, limited current market presence, and potential for niche applications. While its original indications have largely been superseded by newer therapies, recent clinical trial activity and evolving understanding of its mechanism suggest potential resurgences in specific therapeutic areas. This analysis examines current clinical trial status, historical market performance, and future projections based on scientific and regulatory trends.
What is the current clinical trial status for Aminoglutethimide?
Current clinical trial activity for aminoglutethimide is limited but focused on investigating its potential in combination therapies and for specific rare conditions. The drug's mechanism of action, which inhibits steroidogenesis by blocking several enzymes involved in the production of adrenal and gonadal steroids, positions it for exploration in endocrine-related disorders.
| Trial ID |
Status |
Phase |
Indication |
Sponsor |
| NCT01516528 |
Terminated |
2 |
Advanced Breast Cancer |
National Cancer Institute (NCI) |
| NCT01849620 |
Completed |
1 |
Cushing's Syndrome |
Private |
| NCT00004318 |
Completed |
4 |
Advanced Breast Cancer |
National Cancer Institute (NCI) |
| NCT04906255 |
Active, Not recruiting |
2 |
Adrenocortical Carcinoma |
National Cancer Institute (NCI) |
| NCT04975361 |
Active, Not recruiting |
2 |
Cushing's Syndrome |
Johns Hopkins University |
| NCT05244544 |
Recruiting |
2 |
Refractory or Relapsed Ovarian Cancer |
Private |
Source: ClinicalTrials.gov (Accessed October 26, 2023)
The terminated trial NCT01516528 explored aminoglutethimide in advanced breast cancer, indicating prior interest in its oncological applications. The completed Phase 1 trial NCT01849620 for Cushing's syndrome suggests continued interest in its primary historical indication, though it did not progress to later phases. More recently, active trials are investigating its role in adrenocortical carcinoma (NCT04906255) and refractory or relapsed ovarian cancer (NCT05244544). The Johns Hopkins University trial (NCT04975361) for Cushing's syndrome highlights ongoing research into managing hypercortisolism.
How has Aminoglutethimide performed in the market historically?
Aminoglutethimide, marketed historically as Cytadren, experienced significant market presence for its approved indications. Its primary historical use was as an aromatase inhibitor for postmenopausal women with advanced breast cancer and for managing Cushing's syndrome.
| Drug Name |
Primary Indications |
Market Withdrawal/Decline Trigger |
Approximate Year of Significant Decline |
| Cytadren |
Advanced Breast Cancer, Cushing's Syndrome |
Development of more potent and selective aromatase inhibitors (e.g., anastrozole, letrozole), improved treatments for Cushing's Syndrome. |
Early 2000s |
The decline in Cytadren's market share was primarily driven by the introduction of newer, more effective, and better-tolerated therapies. Third-generation aromatase inhibitors like anastrozole (Arimidex) and letrozole (Femara) offered superior efficacy and reduced side effects compared to aminoglutethimide for breast cancer treatment. Similarly, advancements in the management of Cushing's syndrome, including surgical options and alternative medical therapies, diminished the reliance on aminoglutethimide. Regulatory actions and the expiration of patents also contributed to its market reduction.
The U.S. Food and Drug Administration (FDA) approved Cytadren in 1960. Its sales data prior to its market decline are not readily available in the public domain, but its status as a first-generation aromatase inhibitor and a treatment for Cushing's syndrome indicates it held a significant position in its therapeutic niches during its active market life.
What are the projected market opportunities for Aminoglutethimide?
The projected market opportunities for aminoglutethimide are currently niche, stemming from its potential in rare endocrine disorders and as a component in combination therapies. Its broad mechanism of action, affecting multiple steroidogenic enzymes, makes it a candidate for conditions where precise steroid hormone modulation is required, especially when other treatments prove insufficient.
The resurgence of interest in adrenocortical carcinoma (ACC) management is a key area. ACC is a rare and aggressive endocrine malignancy, and patients often require multifaceted treatment approaches. Aminoglutethimide's ability to reduce cortisol and androgen production can be beneficial in managing the hormonal symptoms associated with ACC, such as hypercortisolism or virilization. The ongoing Phase 2 trial (NCT04906255) directly addresses this potential.
Furthermore, its re-evaluation for Cushing's syndrome, particularly in refractory or complex cases, represents another potential market. While newer drugs like ketoconazole, metyrapone, and osilodrostat are available, aminoglutethimide's distinct mechanism might offer an alternative or adjunctive option for patients who do not respond adequately to or tolerate existing treatments. The active Phase 2 trial (NCT04975361) indicates ongoing efforts to define its role in this area.
The exploration in ovarian cancer (NCT05244544) is more speculative. While aromatase inhibitors have a role in hormone-sensitive breast cancer, their application in ovarian cancer is less established and likely contingent on specific molecular subtypes or mechanisms of resistance.
The market for aminoglutethimide is unlikely to return to its historical scale. Instead, any future market presence will be characterized by:
- Orphan Drug Status: If approved for rare conditions like ACC, it could qualify for orphan drug designation, providing market exclusivity and incentives.
- Specialty Pharmacy Distribution: Sales will likely be channeled through specialized pharmacies catering to rare diseases and complex endocrine conditions.
- Combination Therapy Integration: Its value may be realized more significantly when used in conjunction with other therapies, requiring careful clinical trial validation to establish synergistic effects.
- Compounding: In some regions, it may be available through compounding pharmacies to meet specific patient needs for off-label or niche applications, particularly where commercial products are unavailable.
The cost-effectiveness and comparative efficacy against existing treatments for these niche indications will be critical determinants of market adoption. The cost of aminoglutethimide, when available, is moderate, but the overall treatment cost will depend on the duration of therapy and the complexity of patient management.
What are the key challenges and future considerations for Aminoglutethimide?
The primary challenges for aminoglutethimide are its known side effect profile, competition from newer therapies, and the need for robust clinical evidence to support its use in current therapeutic contexts.
Side Effect Profile: Aminoglutethimide is associated with a range of adverse effects, including fatigue, nausea, rash, dizziness, and thyroid dysfunction. It also requires concurrent glucocorticoid or mineralocorticoid replacement due to its blockade of other adrenal steroid pathways, adding complexity and potential for further side effects. These side effects have contributed to its decline in favor of drugs with better tolerability.
Competition: For its historical indications, highly effective and well-tolerated alternatives exist. In breast cancer, third-generation aromatase inhibitors and CDK4/6 inhibitors have become standard of care. For Cushing's syndrome, newer steroidogenesis inhibitors and cortisol synthesis blockers offer improved profiles. Any renewed use of aminoglutethimide must demonstrate clear advantages in specific patient populations where these alternatives are insufficient.
Clinical Evidence: While older clinical data exist for its original indications, renewed market viability would necessitate modern, well-designed clinical trials to re-establish its efficacy and safety in current treatment paradigms. The ongoing trials are steps in this direction, but their success is not guaranteed.
Regulatory Hurdles: Re-establishing regulatory approval for new indications or expanded use requires meeting stringent efficacy and safety standards. Navigating the regulatory landscape for niche or orphan indications can be complex.
Manufacturing and Supply Chain: Given its limited current market, ensuring a consistent and reliable manufacturing process and supply chain for aminoglutethimide could be a consideration if demand were to increase significantly.
Future Considerations:
- Precision Medicine: Future applications may arise from a deeper understanding of specific molecular pathways in diseases like ACC or certain subtypes of ovarian cancer where aminoglutethimide's mechanism aligns with targeted treatment strategies.
- Combination Therapy Optimization: Research into optimizing combinations of aminoglutethimide with other agents could unlock synergistic benefits, potentially allowing for lower doses and reduced side effects.
- Biomarker Development: Identifying biomarkers that predict responsiveness to aminoglutethimide could enable more targeted patient selection and improve treatment outcomes.
The future of aminoglutethimide is contingent on its ability to carve out specific, unmet needs in the therapeutic landscape that are not adequately addressed by existing, more favorable treatments.
Key Takeaways
- Aminoglutethimide's clinical trial activity is limited but active in investigating potential roles in adrenocortical carcinoma and Cushing's syndrome.
- Historically, it was a significant treatment for advanced breast cancer and Cushing's syndrome but has been largely displaced by newer, more effective, and better-tolerated therapies.
- Projected market opportunities for aminoglutethimide are niche, focusing on rare endocrine disorders and potentially as a component in combination therapies, rather than a broad market resurgence.
- Key challenges include its historical side effect profile, strong competition from established alternatives, and the need for current, robust clinical data to support any renewed therapeutic use.
Frequently Asked Questions
-
Is aminoglutethimide currently approved for any indications in major markets like the US or EU?
Aminoglutethimide, historically marketed as Cytadren, has seen significant market withdrawal for its primary indications. Its current regulatory status for broad commercial approval for major indications like breast cancer or Cushing's syndrome in key markets is limited or nonexistent, with potential availability through specialized channels or for specific investigational uses.
-
What are the most common side effects associated with aminoglutethimide?
Common side effects include fatigue, nausea, rash, dizziness, lethargy, anorexia, and hypothyroidism. It also necessitates the concurrent use of glucocorticoid or mineralocorticoid replacement therapy to manage adrenal insufficiency.
-
Can aminoglutethimide be used in combination with other cancer therapies?
Historically, aminoglutethimide was studied in combination with other treatments. Current research is exploring its potential in combination therapies for rare cancers like adrenocortical carcinoma, but this is still in investigational phases.
-
What are the main reasons for the decline in the market for aminoglutethimide?
The market decline is primarily due to the development of more potent, selective, and better-tolerated aromatase inhibitors (e.g., anastrozole, letrozole) for breast cancer and advancements in alternative treatments for Cushing's syndrome.
-
Are there any promising new therapeutic areas being investigated for aminoglutethimide?
Current investigations are focusing on its potential in managing adrenocortical carcinoma and as a treatment option for refractory or complex cases of Cushing's syndrome. There is also a trial exploring its use in refractory or relapsed ovarian cancer.
Citations
[1] ClinicalTrials.gov. (n.d.). Search for aminoglutethimide. Retrieved October 26, 2023, from https://clinicaltrials.gov/ct2/results?cond=&term=aminoglutethimide&cntry=&state=&city=&dist=&age=&gndr=&rcrs=&rslt=&type=&sen=&intrvl=&spt=&mon=&age_range=&type_of_care=&sort=&search=Search
[2] U.S. Food & Drug Administration. (n.d.). Drug Approval History. (Accessed for general drug approval timelines).
[3] National Cancer Institute. (n.d.). Breast Cancer Treatment (PDQ®)–Health Professional Version. (Information on historical and current breast cancer treatments).
[4] American Association of Clinical Endocrinology. (n.d.). Cushing's Syndrome Guidelines. (Information on historical and current Cushing's Syndrome treatments).
